In trading on Tuesday, shares of Novavax, Inc. (Symbol: NVAX) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $7.89 per share. By comparison ...

Deep-pocketed investors have adopted a bullish approach towards Novavax (NASDAQ:NVAX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Shares of Novavax (NVAX), a pharmaceutical company, declined over 6% following the release of its third-quarter results. Though the company reported a lower-than-expected loss and surpassed ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Novavax, Inc. (Symbol: NVAX), where a total of 61,950 contracts have traded so far ...

(RTTNews) - Novavax Inc. (NVAX) released Loss for third quarter that decreased from last year and beat the Street estimates. The company's bottom line totaled -$121.30 million, or -$0.76 per share.

Novavax, Inc. ( NASDAQ:NVAX ) investors will be delighted, with the company turning in some strong numbers with ...

Novavax (NVAX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.26 per share a year ago. These figures are ...

Novavax NVAX incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1. ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced Nuvaxovid sales of $38.2M, which beat consensus ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and ...

Novavax NVAX was in focus this week as investors were ... achieving sustained target inhibition for three months. The Nasdaq Biotechnology Index has lost 1.94% in the past five trading sessions ...

The latest update is out from Novavax ( (NVAX)). Novavax, a leader in vaccine development, announced the FDA’s removal of a clinical hold on their COVID-19-Influenza combination and influenza ...